Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931

[This corrects the article DOI: 10.3389/fimmu.2018.01355.].

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 9; p. 1641
Main Authors Ozkaynak, M Fevzi, Gilman, Andrew L, London, Wendy B, Naranjo, Arlene, Diccianni, Mitchell B, Tenney, Sheena C, Smith, Malcolm, Messer, Karen S, Seeger, Robert, Reynolds, C Patrick, Smith, L Mary, Shulkin, Barry L, Parisi, Marguerite, Maris, John M, Park, Julie R, Sondel, Paul M, Yu, Alice L
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 16.07.2018
Subjects
anti-GD2 chimeric antibody
cytokine biomarkers
cytokines
Immunology
immunotherapy
neuroblastoma
safety
neuroblastoma
cytokines
anti-GD2 chimeric antibody
cytokine biomarkers
safety
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:[This corrects the article DOI: 10.3389/fimmu.2018.01355.].
Bibliography:corrigendum
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correction/Retraction-1
ObjectType-Feature-3
content type line 23
Edited and Reviewed by: Frontiers in Immunology Editorial Office, Frontiers Media SA, Switzerland
Specialty section: This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2018.01641